KOSDAQFood & Beverage222980

Mcnulty Korea

₩2,105▼ 3.88%2026-11-18 close
Market Cap
₩23.2B
Turnover
₩4,326,190
Volume
2K
Shares out.
11M
PER
—
PBR
0.5×
EPS
-₩22
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Coffee core adds pharma and health foods as Q3 turns profitable

Mcnulty Korea is broadening its coffee-centred business with pharmaceutical and health-functional-food subsidiaries, and its Q3 2026 operating profit turned positive, while net profit attributable to controlling shareholders remains in the red.

  1. 1

    Q3 2026 revenue was KRW 28.6 billion, up 15.3% year on year, and operating profit was KRW 1.3 billion, turning positive from an operating loss of KRW 938 million in Q3 2025.

  2. 2

    For 2025, the company recorded an operating loss of KRW 1.1 billion and a net loss attributable to controlling shareholders of KRW 1.27 billion, reverting to losses after the 2024 turn to profit.

  3. 3

    According to a November 2026 news report, the Q3 improvement was supported by recovery at the pharmaceutical and health-food subsidiaries, while the coffee business raised its cumulative operating profit year on year.

  4. 4

    Total equity at the end of Q3 2026 rose to KRW 45.9 billion, up 23.4% from KRW 37.2 billion at the end of 2025, reflecting a land revaluation in the first half.

  5. 5

    Net loss attributable to controlling shareholders totals KRW 234 million over the last four quarters, and the company has posted losses for two consecutive quarters since Q2 2026.

02

Business structure

Mcnulty Korea was founded in 1997 as a coffee manufacturer and processor and listed on KOSDAQ in 2015. In 2020 it spun off its pharmaceutical division into a separate subsidiary, and it has since widened its scope through subsidiaries active in health functional foods and OEM and ODM production.

Coffee's share of revenue has been gradually declining. According to one news report, coffee's share fell from 76.26% in 2022 to 68.45% in 2024, then rose back to 70.54% in the first half of 2025 as the health-food business weakened.

On a 2025 full-year basis, coffee products accounted for 40.56% of revenue, other coffee items for 28.74%, pharmaceutical products for 22.80%, and health functional foods for 6.61%. In the Q1 2026 quarterly filing, coffee products stood at 42.10%, pharmaceutical products at 25.40%, and health-food products at 7.93%.

The coffee lineup centres on Mcnulty-brand beans and instant mixes, and in 2026 the company added cafe-use beans, black coffee and canned-free ready drinks, and liquid tea sticks. The health-food subsidiary launched its own brand based on an individually recognised raw material, black cumin extract.

The largest shareholder, Lee Eun-jung and one related party, holds 57.20% of shares, so management control is concentrated.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩24.8B-₩900M−3.8%
2025Q4₩22B-₩600M−2.8%
2026Q1₩23.5B₩64,837,7850.3%
2026Q2₩26.9B₩300M1.0%
2026Q3₩28.6B₩1.3B4.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩70.2B-₩700M-₩3.2B−1.0%−8.6%114.8%
2023₩78.4B-₩4.2B-₩3.4B−5.3%−10.0%125.3%
2024₩88.8B₩600M₩79,520,5100.6%0.2%112.8%
2025₩96.3B-₩1.1B-₩1.3B−1.1%−3.8%123.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual revenue rose from KRW 70.2 billion in 2022 to KRW 78.4 billion in 2023 (up 11.7% year on year), KRW 88.8 billion in 2024 (up 13.3%), and KRW 96.3 billion in 2025 (up 8.4%), growing for three consecutive years from 2023 through 2025, with 2025 the largest year in the 2022 to 2025 span.

Profit moved differently from sales. The operating loss was KRW 670 million in 2022 and KRW 4.19 billion in 2023, with losses widening in the latter year, before operating profit of KRW 571 million in 2024 marked a turn to profit, and a KRW 1.1 billion operating loss in 2025 marked a return to losses.

Operating margins were -1.0% in 2022, -5.3% in 2023, 0.6% in 2024 and -1.1% in 2025. Net income attributable to controlling shareholders swung to a profit of KRW 79.52 million in 2024 but returned to a loss of KRW 1.27 billion in 2025.

Net income including non-controlling interests, a different measure, was a loss of KRW 352 million in 2024, the smallest loss of the four years, and a loss of KRW 1.28 billion in 2025. Operating cash flow moved from negative KRW 3.14 billion in 2024 to positive KRW 5.45 billion in 2025.

The debt-to-equity ratio rose to 123.8% in 2025 from 112.8% in 2024. Quarterly results bottomed in Q4 2025, when revenue fell 11.0% sequentially to KRW 22 billion and the operating loss was KRW 620 million.

Operating profit turned positive in Q1 2026 at KRW 64.84 million on revenue of KRW 23.5 billion, then rose to KRW 276 million in Q2 (up 325.8% sequentially) and KRW 1.3 billion in Q3 on revenue of KRW 28.6 billion (up 370.8% sequentially and a turn to profit year on year).

Revenue has grown for three consecutive quarters since Q1 2026. Net income attributable to controlling shareholders, by contrast, swung from a KRW 563 million profit in Q1 2026 to a KRW 176 million loss in Q2 and a KRW 436 million loss in Q3.

Because operating profit and controlling-shareholder net results diverged in the same quarters, non-operating items and tax effects deserve separate attention.

05

Industry analysis

Demand for the coffee business is supported by the spread of home-cafe habits and rising demand for premium ground coffee. The company's first-half 2026 earnings commentary noted that coffee sales edged up, but profitability eased somewhat because of cost burdens and higher expenses.

In early November 2026, a market report said cost pressures and export growth had pulled individual food stocks in different directions. Raw-material and cost burdens therefore act as a shared variable across the sector.

The pharmaceutical segment is described as holding steady revenue from contract manufacturing and development work, and a 2025 news report cited brokerage estimates that the global CMO and CDMO market could grow at roughly 15% a year through 2032.

The health-food business is strengthening its position by securing individually recognised raw materials. Competitively, Mcnulty Korea's mix of coffee-based sales plus pharmaceutical and health-food operations is its differentiator.

Against listed coffee peers such as Dong SUH Companies and large domestic food groups, however, its scale in sales and distribution is much smaller. High sensitivity to the price of a single coffee raw material is also a structural weakness.

06

Outlook

The company expects that wider sales of its new products launched in the second half and deeper production collaboration with client companies will support earnings at its subsidiaries, according to a news report dated November 16, 2026.

The pharmaceutical subsidiary is pursuing a stronger over-the-counter portfolio and a larger supply of essential medicines. The health-food subsidiary is expanding OEM and ODM production and has widened production partnerships with other companies, and it has launched its own black-cumin-extract product line.

On the coffee side, the company has been widening distribution through new product launches in 2026, including a trade-show appearance at the Seoul Food 2026 exhibition in June.

On the balance sheet, a first-half 2026 land revaluation lifted total equity, and that adjustment reflects asset value rather than operations, so it should be read apart from the earnings trend.

The next checkpoint is whether the 2026 annual report shows a full-year operating profit, and whether quarterly operating profit gains carry through to net results attributable to controlling shareholders.

07

Valuation

PER
—
PBR
0.5×
ROE
-0.6%
EPS
-₩22
BPS
₩3,998
Dividend per share
₩0

The price-to-book ratio sits below 1x, meaning the shares trade under the company's net asset value. Total equity at the end of 2025 was KRW 37.2 billion, of which KRW 33.1 billion belonged to controlling shareholders.

Total equity rose to KRW 45.9 billion at the end of Q3 2026 after a first-half land revaluation, so book-value multiples should be compared before and after that revaluation. The revaluation gain is a change in equity rather than operating income.

On earnings, the cumulative net loss attributable to controlling shareholders over the last four quarters is KRW 234 million, so a P/E ratio cannot be calculated.

Operating profit was positive in both Q2 and Q3 2026, but controlling-shareholder net results were negative over the same period, so earnings-based comparisons will need a sustained net profit turn first. The dividend yield is below the sector average.

Because the company's history combines loss and profit periods, a single historical multiple band offers limited guidance on where the valuation stands.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Operating profit up for two straight quarters

Operating profit turned positive in Q1 2026, then rose to KRW 276 million in Q2 and KRW 1.3 billion in Q3, a 370.8% sequential gain. Compared with the KRW 938 million operating loss in Q3 2025, the latest quarter marks a swing to profit. Revenue has risen for three consecutive quarters, reaching KRW 28.6 billion in Q3 2026.

Subsidiary recovery becomes visible

According to a news report dated November 16, 2026, the pharmaceutical subsidiary's cumulative nine-month revenue reached KRW 18.7 billion, up 10.6%, and it swung to a KRW 500 million operating profit.

The health-food subsidiary's cumulative revenue rose 72.6% to KRW 9.1 billion and it returned to a KRW 200 million operating profit. The coffee business's cumulative operating profit rose 50.2%.

Larger equity base

Total equity at the end of Q3 2026 was KRW 45.9 billion, up 23.4% from KRW 37.2 billion a year earlier, driven by a first-half land revaluation. At the end of 2025, the debt-to-equity ratio was 123.8% and total liabilities were KRW 46 billion. The revaluation is not an operating gain, but the larger equity base does give the balance sheet more room.

09

Bear factors

Annual losses and cumulative net deficit

The 2025 operating loss was KRW 1.1 billion and the net loss attributable to controlling shareholders was KRW 1.27 billion, a return to losses. The 2023 operating loss of KRW 4.19 billion was much larger.

Over the last four quarters, controlling-shareholder net losses total KRW 234 million, and the company posted losses in both Q2 and Q3 2026.

Pressure on coffee profitability

A corporate earnings commentary dated September 2026 reported that first-half 2026 consolidated operating profit fell 24.9% year on year. The same commentary attributed the coffee business's softer profitability to cost burdens and higher expenses.

Although operating profit turned positive in Q3, the controlling-shareholder net loss widened to KRW 436 million.

Leverage and concentrated ownership

At the end of 2025, the debt-to-equity ratio was 123.8% and total liabilities were KRW 46 billion. The largest shareholder and a related party hold 57.20% of shares, leaving a free float of 39.91% as of September 2026. Foreign ownership is 1.83%. A narrow tradable float keeps trading and governance factors in focus.

10

Risk factors

Cost pressure and business concentration

Coffee accounts for the largest share of revenue on a 2025 full-year basis, combining branded products and other coffee items. Rising raw-material and cost burdens could weigh on profitability again, as the first-half 2026 commentary noted. Whether growth in non-coffee businesses offsets these costs is the key question.

Governance and tradable float

Insiders and related parties hold 57.20%, and the free float is 39.91% as of September 2026, with foreign ownership at 1.83%. In a structure like this, the share price can react sharply to changes in trading volume. Any shift in the ownership structure should be tracked through regulatory filings.

Subsidiary dependence and profit gap

The Q3 improvement relies on recovery at the pharmaceutical and health-food subsidiaries. If new-product sales and production partnerships fall short, that recovery could stall. Because operating profit and controlling-shareholder net results diverged in the same quarters, swings in non-operating items are also a risk. Equity lifted by the revaluation is not a gauge of earnings capacity.

11

What to watch next

  1. End of December 2026

    The 2026 fiscal year closes. The key checks are whether the operating profit positive through nine months holds on a full-year basis and how coffee cost trends evolve in Q4.

  2. End of March 2027

    The deadline for the 2026 annual report falls in this window. The filing will show whether full-year 2026 operating profit and net results attributable to controlling shareholders improved from the 2025 operating loss of KRW 1.1 billion and net loss of KRW 1.27 billion.

  3. March 2027 (expected)

    The annual general meeting is expected to approve the financial statements, following the March 27, 2026 meeting as a reference, and any dividend decision would be confirmed there.

  4. May 15, 2027

    The deadline for the Q1 2027 quarterly report. The comparison will focus on whether profitability holds relative to Q1 2026, when operating profit was KRW 64.84 million and net profit attributable to controlling shareholders was KRW 563 million.

12

Overall view

Mcnulty Korea built its business on coffee and has widened its revenue mix through pharmaceutical and health-food subsidiaries. Revenue rose for three consecutive years from KRW 70.2 billion in 2022 to KRW 96.3 billion in 2025, but profit stayed in the red apart from the KRW 571 million operating profit in 2024.

The quarterly pattern changed in 2026. Operating profit turned positive in Q1, rose in Q2 and Q3, and reached KRW 1.3 billion in Q3, while revenue has grown for three consecutive quarters.

Over the same period, net results attributable to controlling shareholders have been negative since Q2, and the four-quarter total is a net loss of KRW 234 million. Bullish factors include subsidiary recovery, new product launches and a larger equity base after the land revaluation.

Bearish factors include the record of annual losses, coffee cost pressure and concentrated ownership. The price-to-book ratio sits below 1x, but no P/E ratio can be calculated.

The next checkpoints are the operating profit and controlling-shareholder net results in the 2026 annual report, and the Q1 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. wowtv.co.kr
  2. comp.wisereport.co.kr
  3. businesspost.co.kr
  4. edaily.co.kr
  5. edaily.co.kr
  6. mcnultykorea.co.kr
  7. comp.fnguide.com
  8. thinkpool.com
  9. wowtv.co.kr
  10. investing.com
  11. m.news.nate.com
  12. comp.fnguide.com
  13. kind.krx.co.kr
  14. edaily.co.kr
  15. kakaocorp.com

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis